From CRL to buy­out in five months: As­ser­tio to ac­quire Spec­trum in $248M stock deal

Spe­cial­ty phar­ma­ceu­ti­cals com­pa­ny As­ser­tio Hold­ings will buy Spec­trum Phar­ma­ceu­ti­cals in an all-stock deal for about $248 mil­lion, the com­pa­nies said Tues­day morn­ing, just a few months af­ter Spec­trum’s lung can­cer drug was re­ject­ed by reg­u­la­tors.

The deal could ex­pand by $43 mil­lion if Spec­trum hits cer­tain rev­enue mile­stones on its drug Rolve­don, ap­proved last Sep­tem­ber to re­duce in­fec­tion with chemother­a­py-in­duced neu­trope­nia, by the end of 2024 and 2025.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER